2RFE
Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide
Summary for 2RFE
Entry DOI | 10.2210/pdb2rfe/pdb |
Related | 2RF9 2RFD |
Descriptor | Epidermal growth factor receptor, ERBB receptor feedback inhibitor 1 (3 entities in total) |
Functional Keywords | kinase domain, inhibition, dimer, alternative splicing, anti-oncogene, atp-binding, cell cycle, disease mutation, glycoprotein, membrane, nucleotide-binding, phosphorylation, polymorphism, receptor, secreted, transferase, transmembrane, tyrosine-protein kinase, ubl conjugation, cytoplasm |
Biological source | Homo sapiens (human) More |
Cellular location | Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted: P00533 Cytoplasm : Q9UJM3 |
Total number of polymer chains | 6 |
Total formula weight | 156370.83 |
Authors | Zhang, X.,Pickin, K.A.,Bose, R.,Jura, N.,Cole, P.A.,Kuriyan, J. (deposition date: 2007-09-28, release date: 2007-12-04, Last modification date: 2023-08-30) |
Primary citation | Zhang, X.,Pickin, K.A.,Bose, R.,Jura, N.,Cole, P.A.,Kuriyan, J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 450:741-744, 2007 Cited by PubMed Abstract: Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy. Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other. The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a approximately 25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition. PubMed: 18046415DOI: 10.1038/nature05998 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.9 Å) |
Structure validation
Download full validation report